Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins.
The present study was planned to evaluate if a longterm follow-up would show any modification of insulin antibodies in IDDs transferred from porcine to human monocomponent insulins. Nineteen IDDs, treated for more than one year with porcine monocomponent insulins, were transferred to the equivalent formulations of human insulin (Actrapid HM, Monotard HM); insulin antibodies, metabolic control, insulin dose, adverse drug reactions were evaluated during a 42-month follow-up. A reduction of IgG insulin antibodies was observed after 22 months of the follow-up and became significant (2p less than 0.05) at the 42nd month. No significant modification of metabolic control, insulin requirement, or hypoglycaemic episodes were recorded. No adverse events were reported.
Virgili
F
F
Diabetic Unit, Hospital of Mestre, Venice, Italy.
Frigato
F
F
Magnanini
P G
PG
Coronel
G A
GA
Iavicoli
M
M
D000328:Adult; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007328:Insulin / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000032:analysis*; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D061389:Insulin, Regular, Pork; D011994:Recombinant Proteins / Q000627:therapeutic use; D013552:Swine
D007074:Immunoglobulin G; D007328:Insulin; D007330:Insulin Antibodies; D049528:Insulin, Long-Acting; D061389:Insulin, Regular, Pork; D011994:Recombinant Proteins; C000006:insulin, neutral